

COORDINATION OF RETIREMENT AND EFFECTIVE DATES TABLE—Continued

| Existing approved standard | Requirement to be retired or replaced | Proposed standard | New requirement to be implemented | Date for concurrent retirement and implementation                    |
|----------------------------|---------------------------------------|-------------------|-----------------------------------|--|
| PER-004-1 .....            | R3<br>R4                              |                   | R2.1                              |  |
| PER-002-0 .....            | R4                                    | PER-005-1         | R3                                | 1st day of 1st calendar quarter after regulatory approval.           |
| PER-004-1 .....            | R2                                    |                   | R1                                |  |
| PER-004-1 .....            | R1                                    | PER-004-2         | R1                                | 1st day of 1st calendar quarter after regulatory approval.           |
|                            | R5                                    |                   | R2                                |  |
| N/A .....                  | N/A                                   | PER-005-1         | R3.1                              | 1st day of 1st calendar quarter 36 months after regulatory approval. |

[FR Doc. 2010-29717 Filed 11-24-10; 8:45 am]  
BILLING CODE 6717-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 510**

[Docket No. FDA-2010-N-0002]

**New Animal Drugs; Change of Sponsor's Name and Address**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's name from Belcher Pharmaceuticals, Inc., to Belcher Pharmaceuticals, LLC. The sponsor's mailing address will also be changed.

**DATES:** This rule is effective November 26, 2010.

**FOR FURTHER INFORMATION CONTACT:** Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855; 240-276-8300, e-mail: [steven.vaughn@fda.hhs.gov](mailto:steven.vaughn@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Belcher Pharmaceuticals, Inc., 12393 Belcher Rd., suite 420, Largo, FL 33773 has informed FDA that it has changed its name and address to Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd., Largo, FL 33777. Accordingly, the Agency is amending the regulations in 21 CFR 510.600 to reflect this change.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

**List of Subjects in 21 CFR Part 510**

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

**PART 510—NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1), revise the entry for "Belcher Pharmaceuticals, Inc."; and in the table in paragraph (c)(2), revise the entry for "062250" to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

\* \* \* \* \*  
(c) \* \* \*  
(1) \* \* \*

| Firm name and address  | Drug labeler code  |
|--|--|
| * * * * *  | *  |
| Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd., Largo, FL 33777. | 062250   |
| * * * * *  | *  |
| (2) * * *  |  |
| Drug labeler code  | Firm name and address  |
| * * * * *  |  |
| 062250 ....  | Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd., Largo, FL 33777. |
| * * * * *  |  |

Dated: November 19, 2010.

**Elizabeth Rettie,**  
Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 2010-29693 Filed 11-24-10; 8:45 am]  
BILLING CODE 4160-01-P

**DEPARTMENT OF THE INTERIOR**

**Bureau of Ocean Energy Management, Regulation and Enforcement**

**30 CFR Part 285**

[Docket ID: BOEM-2010-0045]

RIN 1010-AD71

**Renewable Energy Alternate Uses of Existing Facilities on the Outer Continental Shelf—Acquire a Lease Noncompetitively**

**AGENCY:** Bureau of Ocean Energy Management, Regulation and Enforcement (BOEMRE), Interior.

**ACTION:** Direct Final rule.

**SUMMARY:** BOEMRE is revising regulations that pertain to noncompetitive acquisition of an Outer Continental Shelf (OCS) renewable energy lease. We are taking this action because the current regulations covering noncompetitive leasing of an OCS renewable energy lease and an unsolicited request for an OCS renewable energy lease are inconsistent. This rulemaking will make the two processes consistent with each other by eliminating an extra step in the noncompetitive leasing process.

**DATES: Effective Date:** This rule becomes effective on January 25, 2011 unless BOEMRE publishes a notice withdrawing this rule before that date.

**Comment Due Date:** Submit comments on the direct final rule by December 27, 2010.

**FOR FURTHER INFORMATION CONTACT:** Timothy Redding at (703) 787-1219.